Potassium para-aminobenzoate and liver function test findings.
Risk of hepatotoxicity has been raised with respect to potassium para-aminobenzoate (Potaba) therapy. In this regard relevant clinical and laboratory hepatic findings in the hospital records of 390 scleroderma patients were analyzed. There were 274 patients who had received potassium para-aminobenzoate at some time and 116 who never received it. No instance was found in which potassium para-aminobenzoate was the cause of an acute hepatic hypersensitivity reaction. There were random or intercurrent abnormalities in hepatic test findings over time, but these actually occurred more often in the group of patients never treated with potassium para-aminobenzoate. Further, there was no evidence that long-term potassium para-aminobenzoate therapy is hepatotoxic. These findings suggest that acute hepatic reaction to potassium para-aminobenzoate is at least uncommon if not rare.
D010129:4-Aminobenzoic Acid / Q000009:adverse effects*; D062365:Aminobenzoates / Q000009:adverse effects*; D001663:Bilirubin / Q000032:analysis; D056486:Chemical and Drug Induced Liver Injury; D002675:Child, Preschool; D006801:Humans; D008111:Liver Function Tests; D012306:Risk
D062365:Aminobenzoates; D001663:Bilirubin; D010129:4-Aminobenzoic Acid